 The European Medicines Agency EMA has granted orphan drug designation to Stealth BioTherapeutics Corps NASDAQ: MITO elamipretide for Barth syndrome, an ultra-rare genetic condition. Barth syndrome is characterized by cardiac abnormalities, often leading to heart failure and reduced life expectancy, recurrent infections, muscle weakness, and delayed growth. 